Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01945138
Other study ID # CLTPIAT2013
Secondary ID 21856
Status Completed
Phase N/A
First received August 19, 2013
Last updated December 9, 2015
Start date February 2014
Est. completion date December 2015

Study information

Verified date December 2015
Source University of Minnesota - Clinical and Translational Science Institute
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the effectiveness of closed loop insulin pump therapy to control blood sugar following total pancreatectomy and islet auto-transplantation (TPIAT).


Description:

OBJECTIVES AND HYPOTHESES The main objective of this study is to determine if a closed loop insulin system can successfully achieve tighter blood sugar control than the current multiple daily injection regimen. The investigators hypothesize that the average blood glucose will be lower in the closed loop group than the control group, there will be less glucose variability in the closed loop group than the control group, and there will be less total time spent in hyperglycemia and hypoglycemia in the closed loop group than in the control group. The investigators also will investigate insulin requirements and islet function in the first 6 months post-transplant in the closed loop group The investigators hypothesize that the insulin requirements will be lower and the C-peptide levels higher in the closed loop group than in the control group.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date December 2015
Est. primary completion date June 2015
Accepts healthy volunteers No
Gender Both
Age group 21 Years to 64 Years
Eligibility Inclusion Criteria:

- Patients undergoing total pancreatectomy and islet auto-transplantation.

- Patients ages 21 to 64 years old

Exclusion Criteria:

- Preexisting diabetes

- Use of acetaminophen during study period, which interferes with CGM sensor function

- Any medical condition requiring corticosteroids

- Severe Psychiatric disease or developmental delays, that might interfere with the ability to provide informed consent

- Any other medical condition which in the opinion of the investigators impairs the person's ability to safely participate in the trial

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Device:
Closed Loop Insulin
The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).

Locations

Country Name City State
United States University of Minnesota Minneapolis Minnesota

Sponsors (3)

Lead Sponsor Collaborator
University of Minnesota - Clinical and Translational Science Institute Medtronic Diabetes, University of Minnesota, MN

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Study Period: Average Serum BG Mean blood glucose value: a single report of the average of the analytical blood glucose values will be computed and compared between the pump and control groups. 3 days of investigation period Yes
Primary Study Period: Serum BG Standard Deviation Measure of glycemic variability. This is the standard deviation in all serum BG values for each individual patient. 3 days of investigation period No
Secondary Study Period: Continuous Glucose Monitor (CGM) BG Average Continuous glucose monitoring sensor data: The CGM's in the pump and control groups will collect glucose readings continuously over a 72 hour period continuously over the 72 hour investigational period Yes
Secondary Study Period: Continuous Glucose Monitor Standard Deviation of BG measure of glycemic variability by CGM. This is the standard deviation within each patient for all CGM glucose readings. continuous over the 72 hour investigation period No
Secondary Study Period: Percent Time BG in Range 70-140 mg/dL Additional measure of glycemic variability continuous over the 72 hour investigation period No
Secondary Study Period: CGM Area Under the Curve (AUC) With Glucose < 70 mg/dL Calculated as the area under the curve on the CGM tracing that the glucose is under 70 mg/dL. continuous over the 72 hour investigation period No
Secondary Study Period: % of Time CGM BG <70 mg/dL continuous over the 72 hour investigation period No
Secondary Study Period: CGM AUC With Glucose> 140 mg/dL continuous over the 72 hour investigation period No
Secondary Study Period: % of Time CGM BG > 140 mg/dL continuous over the 72 hour investigation period No
Secondary Study Period: Morning C-peptide A single C-peptide measurement collected daily x 3 days, collected at random (meaning not in a fasting state) each morning. Expressed as average for each patient. Average of 3 day study period No
Secondary Study Period: Daily Insulin Needs Calculated as total daily dose of insulin. Average of 3 day study period No
Secondary Day 14 Follow-Up: Average Serum BG Day 14 Follow-Up No
Secondary Day 14 Follow-Up: C-Peptide Day 14 Follow-Up: No
Secondary Day 28 Follow-Up: Average Serum BG Day 28 Follow-Up No
Secondary Day 28 Follow-Up: C-Peptide Day 28 Follow-Up No
Secondary 6 Month Follow-Up: A1c 6 Month Follow-Up: No
Secondary 6 Month Follow-Up: Total Daily Insulin Dose 6 Month Follow-Up: No
Secondary 6 Month Follow-Up: Fasting BG 6 Month Follow-Up: No
Secondary 6 Month Follow-Up: Peak C-Peptide 6 Month Follow-Up: No
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A